Singer L, Schlienger J L, Kammerer F, Stephan F
Encephale. 1979;5(2):171-88.
The treatment by lithium is known to involve certain endocrine complications. Those concerning the thyroid function, with risk of a frank hypothyroidy, are the most important. Aiming to appreciate the frequence and the intensivity of the endocrine effects of lithium, the thyroid parameters and the steady state of the hypothalamo-pituitary-thyroid axis were tested using the TRH test in 52 patients with maniaco-depressive psychosis with special attention to TSH, prolactin and growth hormone: 24 out of them were treated for 1 month to 6 years by lithium; the 28 others were considered as controls. The lithium treatment involves a decrease in the free thyroxine index (1.78 +/- 0.09 vs 2.16 +/- 0.09; p less than 0.01), an increase in the mean baseline TSH level (5.80 +/- 1.49 vs 2.70 +/- 0.24 microU/ml; p less than 0.05) and a noteworthy increase in the TSH responsiveness to TRH (22.7 +/- 2.14 vs 9.75 +/- 1.63 microU/ml; p less than 0.005). The TSH supranormal responses were neither correlated with the length of the treatment nor with the age of the patients. They appear as the consequence of a decrease in the thyroidal hormone secretion. The basal and stimulated prolactinemias remain comparable in the two groups of patients and no response of growth hormone occured after TRH. The TRH test must be considered as a useful complement for the surveillance of the patients treated with lithium because it permits to diagnose early the lithio-induced thyroid dysfunction.
已知锂治疗会引发某些内分泌并发症。其中与甲状腺功能相关的并发症最为重要,存在明显甲状腺功能减退的风险。为了评估锂的内分泌效应的发生率和强度,我们对52例躁狂抑郁症患者进行了促甲状腺激素释放激素(TRH)试验,检测甲状腺参数以及下丘脑 - 垂体 - 甲状腺轴的稳态,特别关注促甲状腺激素(TSH)、催乳素和生长激素:其中24例患者接受锂治疗1个月至6年;另外28例被视为对照组。锂治疗导致游离甲状腺素指数降低(1.78±0.09对2.16±0.09;p<0.01),平均基础TSH水平升高(5.80±1.49对2.70±0.24微单位/毫升;p<0.05),并且TSH对TRH的反应显著增加(22.7±2.14对9.75±1.63微单位/毫升;p<0.005)。TSH超常反应与治疗时长和患者年龄均无相关性。它们似乎是甲状腺激素分泌减少的结果。两组患者的基础和刺激状态下的催乳素血症仍具有可比性,TRH刺激后生长激素无反应。TRH试验必须被视为监测锂治疗患者的有用补充手段,因为它能够早期诊断锂诱导的甲状腺功能障碍。